A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Secondary Progressive Multiple Sclerosis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 54 (planned)
- Started
- Nov 15, 2023
- Main results expected
- Sep 2026
- Fully finished
- Oct 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The number of patients with adverse event (AE) reports.
Measured over: Throughout the study, an average of 12 weeks (3 months).
Changes in the Total Nasal Symptom Score (TNSS).
Measured over: TNSS is performed during the Screening Visit and during the Treatment Period at the first visit of Cycle 1, Cycle 2, Cycle 3, and Cycle 4 (each Cycle is 3 weeks).
Change from baseline for [18F]PBR06-positron emission tomography (PET) scans for microglial activation after 12 weeks (3 months) of study treatment.
Measured over: Subjects will undergo PET imaging prior to Week 1 (i.e., prior to dosing) and after Week 12 (after Cycle 4 at the PET sub-study site).
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06292923 · record last updated 2026-07-02 · checked 2026-11-09 15:36 UTC